MedTrace Logo

Treating Congestive Heart Failure Using a Device to Remove Cholesterol

NCT00510601 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2016-01-13

No results posted yet for this study

Summary

A pilot study to examine the effects of LDL-Apheresis on patients with Stage III Congestive Heart Failure.

Study hypothesis: Decreased blood viscosity from receiving LDL-apheresis will decrease workload on the heart and improve symptoms associated with the progression of Congestive Heart Failure

Conditions

  • Heart Decompensation

Interventions

DEVICE

Kaneka Liposorber

LDL-apheresis on a bi-weekly basis

Sponsors & Collaborators

  • Kaneka Medical America LLC

    collaborator INDUSTRY

  • Patrick Moriarty, MD, FACP, FACC

    lead OTHER

Principal Investigators

  • Patrick Moriarty, M.D. · University of Kansas Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-31
Primary Completion
2011-07-31
Completion
2011-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00510601 on ClinicalTrials.gov